SWOG 1400 aka Lung-MAP – Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Note: The ECOG-ACRIN Cancer Research Group is participating in the Lung Cancer Master Protocol (Lung-MAP), a unique collaborative trial to establish a National Clinical Trials Network mechanism for genomically screening large but homogeneous cancer populations and matching the genomic profile of a patient’s tumor with a biomarker-driven substudy. Substudies compare new targeted therapy or targeted therapy combinations to standard care therapy.

Physician and Research Staff Educational Materials:

These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.

  • S1400 Site Process Summary for ECOG-ACRIN Member Institutions: study goal, substudy goals, trial schema, sources and amounts of case reimbursements/credits, full listing of contact information for study and substudy chairs, and instructions for how sites can participate, all in a four-page brochure prepared by the ECOG-ACRIN Clinical Education and Awareness Team.

Information and Assistance from the National Cancer Institute:

  • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.

Additional Information on Lung-MAP.org: Displayed below is an interactive view of the dedicated website for Lung-MAP. If you are experiencing technical difficulties with this view, visit lung-map.org.